CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record, with a small difference in title or year; 3 of the 3 references it cites were found in a registry or an index.

Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network

Bessone, Fernando, Hernandez, Nelia, Medina-Caliz, Inmaculada, García-Cortés, Miren, Schinoni, María I., Mendizabal, Manuel, Chiodi, Daniela, Nunes, Vinicius, Ridruejo, Ezequiel, Pazos, Ximena, Santos, Genario, Fassio, Eduardo, Parana, Raymundo, Reggiardo, Virginia, Tanno, Hugo, Sanchez, Adriana, Tanno, Federico, Montes, Pedro, Tagle, Martin, Arrese, Marco, Brahm, Javier, Girala, Marcos, Lizarzabal, M. Isabel, Carrera, Enrique, Zerega, Alina, Bianchi, Carla, Reyes, Laura, Arnedillo, Daina, Cordone, Antonella, Gualano, Gisela, Jaureguizahar, Fernanda, Rifrani, Gabriel, Robles-Díaz, Mercedes, Ortega-Alonso, Aida, Pinazo-Bandera, José M., Stephens, Camilla, Sanabria-Cabrera, Judith, Bonilla-Toyos, Elvira, Niu, Hao, Alvarez-Alvarez, Ismael, Lucena, M. Isabel, Andrade, Raul J.·2025·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2024.06.030
Open this paper in CoChat — free account

Abstract

Background & aims Latin America is a region of great interest for studying the clinical presentation of idiosyncratic drug-induced liver injury (DILI). A comprehensive analysis of patients enrolled into the LATINDILI Network over a decade is presented. Methods Demographics, clinical presentation, histological findings and outcome of prospectively recruited DILI cases in the LATINDILI Network were analyzed. Suspected culprit drugs were classified according to the Anatomical Therapeutic Chemical classification. Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) scale. Results Overall, 468 idiosyncratic DILI cases were analyzed (62% women; mean age, 49 years). Hepatocellular injury predominated (62%); jaundice was present in 60% of patients, and 42% were hospitalized. Of the cases, 4.1% had a fatal outcome, and 24 patients (12%) developed chronic DILI. The most common drug classes were systemic anti-infectives (31%), musculoskeletal agents (12%), antineoplastic and immunomodulating agents (11%), and herbal and dietary supplements (9%). Notably, none of the patients with DILI due to antibacterials or immunosuppressants had a fatal outcome. In fact, Hy's law showed to have drug-specific predictive value, with anti-tuberculosis drugs, nimesulide, and herbal and dietary supplements associated with the worst outcome, whereas DILI caused by amoxicillin-clavulanate, nitrofurantoin, and diclofenac, which fulfilled Hy's law, did not have a fatal outcome. C…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2024.06.030

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Expert judgement is the approach used to assess causality in large prospective DILI registries such as the Spanish, Latin American, European, and DILIN registries.

    “Expert judgement is the approach used to assess causality in large prospective DILI registries such as the Spanish, the Latin American, the European, or the DILIN.”

    From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [54]

  • In response to limitations of expert judgement, the Spanish, LATINDILI and Pro-Euro DILI networks combined evaluation of suspected DILI cases by three experts with further assessment using causality scales, while DILIN developed a structured expert opinion process.

    “In response to these limitations, the Spanish, LATINDILI and Pro‐Euro DILI networks have combined the evaluation of suspected DILI cases by three experts and further assessment using causality scales, while the DILIN has developed a structured expert opinion process.”

    From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [54]

  • The pharmacological groups most frequently involved in DILI are antimicrobials, cardiovascular system drugs, and musculoskeletal system drugs, although this varies according to country and areas of the world.

    “The pharmacological groups most frequently involved in DILI are antimicrobials, cardiovascular system drugs, and musculoskeletal system drugs, although this varies according to country and areas of the world [3][4][5][6].”

    From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [6]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. Bessone, 2019, When the creation of a consortium provides useful answers: experience of the Latin American DILI Network (LATINDILIN), Clin Liver Dis (Hoboken), 13, 51, 10.1002/cld.778 · DOI
  2. Hernández, 2014, Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports, Ann Hepatol, 13, 231, 10.1016/S1665-2681(19)30886-5 · DOI
  3. Santos, 2021, Profile of herbal and dietary supplements induced liver injury in Latin America: a systematic review of published reports, Phytother Res, 35, 6, 10.1002/ptr.6746 · DOI
  4. Bessone, 2016, The Latin American DILI Registry experience: a successful ongoing collaborative strategic initiative, Int J Mol Sci, 17, 313, 10.3390/ijms17030313 · DOI
  5. Stephens, 2021, Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry, J Hepatol, 75, 86, 10.1016/j.jhep.2021.01.029 · DOI
  6. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI
  7. Danan, 1993, Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  8. Robles-Diaz, 2014, Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury, Gastroenterology, 147, 109, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  9. Medina-Caliz, 2016, Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury, J Hepatol, 65, 532, 10.1016/j.jhep.2016.05.003 · DOI · Paper page
  10. Charlson, 1994, Validation of a combined comorbidity index, J Clin Epidemiol, 47, 1245, 10.1016/0895-4356(94)90129-5 · DOI · Paper page
  11. Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI
  12. García-Cortés, 2023, Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries, Liver Int, 43, 1749, 10.1111/liv.15623 · DOI
  13. Medina-Cáliz, 2024, Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries, Arch Toxicol, 98, 303, 10.1007/s00204-023-03630-0 · DOI
  14. Pinazo-Bandera, 2024, Rechallenge in idiosyncratic drug-induced liver injury: an analysis of cases in two large prospective registries according to existing definitions, Pharmacol Res, 203, 10.1016/j.phrs.2024.107183 · DOI
  15. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  16. Devarbhavi, 2021, The Indian Network of Drug-Induced Liver Injury: etiology, clinical features, outcome and prognostic markers in 1288 patients, J Clin Exp Hepatol, 11, 288, 10.1016/j.jceh.2020.11.002 · DOI
  17. Björnsson, 2023, A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry, Liver Int, 43, 115, 10.1111/liv.15378 · DOI · Paper page
  18. Aiso, 2019, Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan, Hepatol Res, 49, 105, 10.1111/hepr.13288 · DOI · Paper page
  19. Atun, 2015, Health-system reform and universal health coverage in Latin America, Lancet, 385, 1230, 10.1016/S0140-6736(14)61646-9 · DOI
  20. Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
  21. Weersink, 2021, Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old, Clin Pharmacol Ther, 109, 1147, 10.1002/cpt.2108 · DOI
  22. Ghabril, 2019, Development and validation of a model consisting of comorbidity burden to calculate risk of death within 6 months for patients with suspected drug-induced liver injury, Gastroenterology, 157, 1245, 10.1053/j.gastro.2019.07.006 · DOI · Paper page
  23. Bessone, 2022, Herbal and dietary supplements-induced liver injury in Latin America: experience from the LATINDILI Network, Clin Gastroenterol Hepatol, 20, e548, 10.1016/j.cgh.2021.01.011 · DOI · Paper page
  24. Bessone, 2021, Drug-induced liver injury: a management position paper from the Latin American Association for Study of the liver, Ann Hepatol, 24, 10.1016/j.aohep.2021.100321 · DOI
  25. Robles-Diaz, 2015, Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids, Aliment Pharmacol Ther, 41, 116, 10.1111/apt.13023 · DOI · Paper page
  26. Stolz, 2019, Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors, Aliment Pharmacol Ther, 49, 1195, 10.1111/apt.15211 · DOI
  27. Stapelbroek, 2010, Liver disease associated with canalicular transport defects: current and future therapies, J Hepatol, 52, 258, 10.1016/j.jhep.2009.11.012 · DOI
  28. Nash, 2024, Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia, Aliment Pharmacol Ther, 59, 953, 10.1111/apt.17906 · DOI
  29. Bessone, 2023, Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries, Arch Toxicol, 97, 593, 10.1007/s00204-022-03419-7 · DOI
  30. Bessone, 2021, Serious liver injury induced by Nimesulide: an international collaborative study, Arch Toxicol, 95, 1475, 10.1007/s00204-021-03000-8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Bessone, F., Hernandez, N., Medina-Caliz, I., García-Cortés, M., Schinoni, M. I., Mendizabal, M., Chiodi, D., Nunes, V., Ridruejo, E., Pazos, X., Santos, G., Fassio, E., Parana, R., Reggiardo, V., Tanno, H., Sanchez, A., Tanno, F., Montes, P., Tagle, M., Arrese, M., Brahm, J., Girala, M., Lizarzabal, M. I., Carrera, E., Zerega, A., Bianchi, C., Reyes, L., Arnedillo, D., Cordone, A., Gualano, G., Jaureguizahar, F., Rifrani, G., Robles-Díaz, M., Ortega-Alonso, A., Pinazo-Bandera, J. M., Stephens, C., Sanabria-Cabrera, J., Bonilla-Toyos, E., Niu, H., Alvarez-Alvarez, I., Lucena, M. I., & Andrade, R. J.
ORCID
Andrade, Raul J.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2025-01
Volume
23
Issue
1
Pages
89-102
ISSN
1542-3565
DOI
10.1016/j.cgh.2024.06.030
Cited by
24
References
3
Language
en
Licence
Funders
  • Junta de Andalucía (POSTDOC_21_00780)
  • Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultra huérfanos (CM21/00074, JR21/00066)
  • European Metrology Programme for Innovation and Research (101095679, HORIZON-HLTH-2022-STAYHLTH-02)
  • European Geosciences Union (PT23/00137, PI21/01248, PT20/00127)
  • Agencia de Desarrollo Económico
  • Instituto de Salud Carlos III
  • EGI Federation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review